NetworkNewsBreaks – Arcus Biosciences Inc. (NYSE: RCUS) Featured in Mizuho Securities Research Report
Arcus Biosciences Inc. (NYSE: RCUS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Shares of RCUS are trading up ~50% after hours which we believe to be associated with a Bloomberg article indicating that GILD (Buy, $81 PT, covered by Mizuho analyst Salim Syed) is considering acquiring a stake in the company. RCUS has a number of I/O clinical assets, with AB154 (anti-TIGIT) receiving considerable attention following the advancement of a competitor candidate (Roche's tiragolumab) into Phase III studies earlier this year. Bottom line for us that is that partner activity…